Dynavax Technologies Corp

Jefferies Lowers Numbers on Dynavax (DVOX), Keeps "Buy" Rating

Jefferies Maintains a 'Buy' on Dynavax Technologies (DVAX); Broad Adult Label Should Be A Positive For Heplisav and Diabetes Opportunity

Top Stock Alerts for Day Traders: Entropic, Activision Blizzard, Dynavax Technologies

FDA expands age range for Dynavax vaccine to 18-70 years

8 Stocks Under $10 Moving Higher

Dynavax expanded Heplisav label a significant positive, says William Blair

Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA

Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018

McNicoll Lewis & Vlak Starts Dynavax Technologies (DVAX) at Buy

Dynavax, AstraZeneca agree to advance AZD1419

Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma

The 2 Best-Performing Sectors Over the Last Decade

Dynavax initiates proof of mechanism trial in lupus patients

Dynavax Initiates Proof of Mechanism Trial in Lupus Patients

Dynavax and Vical -- Undervalued and Gaining Attention

Dynavax and Vical -- Undervalued and Gaining Attention

Healthcare Sector: Analyzing Noteworthy Buys And Sells By Insiders Last Week

Dynavax raises $64M in stock sale, chairman buys 160,000 shares

Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock

Dynavax plans $60 million stock sale

Dynavax 24M share Spot Secondary priced at $2.50

Dynavax (DVAX) Prices 24M Common Offering at 3.9% Discount

Dynavax Prices Public Offering of Common Stock

High R&D Costs Weigh on Dynavax Technologies and Marina Biotech

High R&D Costs Weigh on Dynavax Technologies and Marina Biotech

Dynavax files to sell common stock, no amount given

Dynavax Announces Proposed Public Offering of Common Stock

Dynavax Technologies Corp. Reports Operating Results (10-Q)

Dynavax confirms Heplisav submission strategies with FDA and EMA

Dynavax Confirms HEPLISAV(TM) Submission Strategies With U.S. FDA and EMA

Dynavax releases results of hepatitis B vaccine phase-3 trial

Dynavax reports Q3 EPS (12c) vs. consensus (13c)

Dynavax Reports Third Quarter 2011 Financial Results

Dynavax can surf CDC call for wider hep B vaccination after positive Heplisav data

Dynavax (DVAX) Reports Encouraging Data from HEPLISAV Phase 3

Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018

Dynavax reports positive Phase 3 results from HEPLISAV study

Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis B

Dynavax to get $3 million in expanded GlaxoSmithKline deal

Dynavax to host analyst and investor day